Pandemic Flu Preparedness: A Manufacturing Perspective - Scalability, speed, and biosafety will be critical in the event of an influenza pandemic. The containment needs of an avian flu strain could pr

ADVERTISEMENT

Pandemic Flu Preparedness: A Manufacturing Perspective
Scalability, speed, and biosafety will be critical in the event of an influenza pandemic. The containment needs of an avian flu strain could present additional challenges.


BioPharm International


Conclusion

New funding as a result of the global pandemic influenza action plan to increase supply has spurred vaccine industry initiatives in planning manufacturing capacity. Given uncertain factors and the potential surge capacity requirement involved in the avian or pandemic influenza vaccine market, preparedness could come at a high cost. Although such a pre-emptive measure is the right step forward, a key question the vaccine manufacturing community must ask is "What production and facility concepts should be applied to provide a good business case?"

Aeby Thomas is a process engineer at NNE Pharmaplan, Søborg, Denmark, +45 4444 7777,
. At the same company, Niels Guldager is a specialist, business consulting services, and Klaus Hermansen is a senior specialist, business consulting services.

Suggested Reading

1. World Health Organization (WHO). Global pandemic influenza action to increase vaccine supply. Geneva, Switzerland: WHO Epidemic and Pandemic Alert Response (EPR) Publications; 2006 [cited July 1, 2007]. Available from: http://www.who.int/csr/resources/publications/influenza/CDS_EPR_GIP_2006_1.pdf.

2. World Health Organization (WHO). Working paper 1: Increasing production capacity for pandemic influenza vaccines. Draft doc., v. 4. Geneva, Switzerland: WHO Initiative for Vaccine Research (IVR); n.d. [cited July 1, 2007]. Available from: http://www.who.int/vaccine_research/diseases/influenza/Working_Paper_1.pdf.

3. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Influenza Vaccine Supply International Task Force (IVS ITF). R&D for avian/pandemic influenza vaccines. Geneva, Switzerland: IFPMA; 2006 October 17 [cited July 1, 2007]. Available from: http://www.ifpma.org/Influenza/content/pdfs/Table_Avian_Pandemic_Influenza_RnD_17Oct06.pdf

4. Rappouli R. Cell-culture based vaccine production: Technological options. The Bridge [serial online] 2006 Fall [cited July 1, 2007];36(3). Available from: http://www.nae.edu/nae/bridgecom.nsf/weblinks/MKEZ-6SZR4L?OpenDocument.

5. Galliher PM. Review of single-use technologies in biomanufacturing. Worcester Polytechnic Institute, Bioengineering Institute Symposium: New Developments in Biomanufacturing. 2007 Feb 20; Worcester, MA; 2007 [Cited July 1, 2007]. Available from: http://www.wpi.edu/Images/CMS/BEI/parrishgalliher.pdf.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

UPS' Pain in the Supply Chain Results
September 23, 2014
Merck KGaA Announces Acquisition of Sigma-Aldrich for $17 Billion
September 22, 2014
Pandemic Vaccine Facility Dedicated in Texas
September 19, 2014
GSK Fined in China Bribery Scandal
September 19, 2014
Guideline Delineates How to Implement GS1 Standards to Support DSCSA
September 19, 2014
Author Guidelines
Source: BioPharm International,
Click here